Year-End Review | Professor Jianxiang Wang: Targeted New Drugs Lead the Wave of Advances in AML Treatment, Immunotherapy Also on the Rise!
Acute Myeloid Leukemia (AML) is a malignant clonal disease originating from hematopoietic stem cells. Affected myeloid cells (leukemic cells) undergo uncontrolled proliferation, differentiation disorders, and blocked apoptosis, accumulating in the bone marrow and other hematopoietic tissues. This inhibits normal hematopoietic function and infiltrates organs such as lymph nodes, liver, and spleen, leading to clinical features including anemia, infections, bleeding, and leukemic cell infiltration. As the most common hematologic malignancy, research in the field of AML, both basic and clinical, has never ceased, yielding continuous breakthroughs. So, what significant advancements has the AML field witnessed in the past year? "Oncology Frontier" has invited Professor Jianxiang Wang from the Institute of Hematology, Chinese Academy of Medical Sciences, to meticulously review various developments in the AML domain. The summary is compiled below.